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Abstract  48 
 49 
Melanoma patients have a high risk of developing brain metastasis, which is associated with 50 
a dismal prognosis. During early stages of metastasis development, the blood-brain barrier (BBB) is 51 
likely intact, which inhibits sufficient drug delivery into the metastatic lesions. We investigated the 52 
ability of the peptide, K16ApoE, to permeabilize the BBB for improved treatment with targeted 53 
therapies preclinically. DCE-MRI was carried out on NOD/SCID mice to study the therapeutic 54 
window of peptide-mediated BBB permeabilization. Further, both in vivo and in vitro assays were 55 
used to determine K16ApoE toxicity and to obtain mechanistic insight into its action on the BBB. 56 
The therapeutic impact of K16ApoE on metastases was evaluated combined with the mitogen-57 
activated protein kinase pathway inhibitor dabrafenib, targeting BRAF mutated melanoma cells, 58 
which is otherwise known not to cross the intact BBB. Our results from the DCE-MRI experiments 59 
showed effective K16ApoE-mediated BBB permeabilization lasting for up to one hour. Mechanistic 60 
studies showed a dose-dependent effect of K16ApoE caused by induction of endocytosis. At 61 
concentrations above IC50, the peptide additionally showed nonspecific disturbances on plasma 62 
membranes. Combined treatment with K16ApoE and dabrafenib reduced the brain metastatic 63 
burden in mice and increased animal survival, and PET/CT showed that the peptide also facilitated 64 
the delivery of compounds with molecular weights as large as 150 kDa into the brain. To conclude, 65 
we demonstrate a transient permeabilization of the BBB, caused by K16ApoE, that facilitates 66 
enhanced drug delivery into the brain. This improves the efficacy of drugs that otherwise do not 67 
cross the intact BBB.  68 
 69 
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Introduction 70 
Brain metastasis is a frequently reported complication for patients with cutaneous melanoma 71 
where the average survival time, if untreated, is 3–5 months. Current treatment strategies involve 72 
surgery, systemic therapy, radiotherapy and/or radiosurgery (1). This can to some extent increase 73 
the survival time, yet with a divergent treatment efficacy, emphasizing the need for new treatment 74 
options.  75 
It is well known that melanomas are molecularly heterogeneous (2) and immunogenic 76 
tumors (3), properties that have been exploited for drug development (4). For instance, it has been 77 
shown that the serine/threonine kinase protein BRAF is a key molecular driver of metastatic 78 
melanoma, which has led to the development of several BRAF inhibitors (BRAFi). Furthermore, 79 
immune checkpoint inhibitors such as PD-1/PD-L1 have shown a strong clinical efficacy in clinical 80 
trials for melanoma (5-7). However, a recurring issue is that many of these drugs are too large to 81 
cross the intact interface between circulating blood and the brain parenchyma, i.e. the blood-brain 82 
barrier (BBB) (8,9). The BBB consists of vascular endothelial cells linked by tight junctions, 83 
encircled by astrocytic end-feet and pericytes leading to a selective barrier that determines the entry 84 
of molecules into the brain (10). This barrier represents in many instances a major obstacle for 85 
systemic brain metastasis treatment. Compounds that consist of more than eight to ten hydrogen 86 
bonds and are larger than 400–500 Da are prohibited from entering the brain. All large molecular 87 
drugs, such as antibodies, and 98% of small molecular drugs are excluded from the brain by the 88 
BBB (11). The brain is thus considered as a sanctuary site for metastatic growth (12) and the 89 
exposure to drugs is lower in brain metastases than systemic metastases. This is not only ascribed to 90 
the presence of the BBB but also the blood-tumor barrier (BTB) (13). The BTB differs from the 91 
BBB in that the vascular system is no longer surrounded by the other, normal BBB components, but 92 
tumor cells. Due to this structural difference, the BTB is proposed to be more permeable than the 93 
BBB (14). Micro-metastases, i.e. lesions smaller than 1 mm
3
, usually have  a lower permeability 94 
than larger metastases, in which the BTB might be compromised as a result of tumor growth (15). 95 
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Systemic therapy may therefore show efficacy on larger metastatic lesions, whereas micro-96 
metastases receive subtherapeutic drug concentrations, which can contribute to treatment resistance 97 
(16). However, it has also been shown that there is not necessarily a straightforward association 98 
between brain metastasis size and drug uptake. Within the same lesion, the distribution can vary up 99 
to 10-fold (17). Also, melanoma patients with advanced disease can present with multiple brain 100 
metastases of different sizes with varying BTB integrities, further challenging systemic treatment 101 
(18). Several strategies have therefore been developed to temporarily disrupt the BBB for improved 102 
drug delivery such as focused ultrasound combined with circulating microbubble contrast agents 103 
(19-21), hyperosmotic opening (22-24) and radiotherapy (25). Other strategies involve the 104 
circumvention of  the BBB by convection-enhanced delivery (26), viral-mediated or liposomal 105 
delivery (27), carrier molecules (28) and polymer wafers (29). These strategies have shown both 106 
strengths and weaknesses, but with limited success and many with apparent side effects (30,31).  107 
It has previously been reported that the synthetic peptide K16ApoE can carry relatively 108 
large compounds into the mouse brain through the low-density lipoprotein receptor (LDLR) 109 
pathway (32). The use of K16ApoE in a therapeutic setting in vivo, however, has not been 110 
investigated. Here we determined, using advanced magnetic resonance imaging (MRI) techniques, 111 
the length of the therapeutic time window of K16ApoE BBB permeabilization in NOD/SCID mice 112 
and also its in vivo toxicity profile. Moreover, the morphological and functional effects of the 113 
peptide on cells and tissues were elucidated. In addition, we assessed the ability of K16ApoE to 114 
enhance drug delivery of a clinically active BRAFi (dabrafenib) on preclinical brain metastases, 115 
which was our main objective with this study. Finally, using PET/CT as an in vivo biodistribution 116 
tool for studying brain penetration, we assessed the potential of the peptide to deliver compounds to 117 
the brain with a size range corresponding to clinically relevant immune checkpoint inhibitors.  118 
 119 
 120 
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Materials and methods 121 
 122 
K16ApoE peptide design and production 123 
The K16ApoE peptide has the following amino acid sequence: KKKK-KKKK-KKKK-124 
KKKK-LRVR-LASH-LRKL-RKRL-LRDA with a molecular weight (MW) of 4.521.79 Da. The 125 
synthesis and characterization of the peptide is elaborated in Supplementary Materials. Briefly, a 126 
series of 16 lysine residues (K16) was covalently linked to the 20 amino acid part of the low-density 127 
lipoprotein receptor binding segment of apolipoprotein E (ApoE).  128 
 129 
Cell culture  130 
5 cell lines were used as constituents of the in vitro model system of the BBB, namely 131 
Mabin-Darby Canine Kidney (MDCK) cells, MDCK II, rat brain endothelial cells 4 (RBE4), human 132 
brain endothelial cells (hCMEC/D3) and human brain astrocytes (SC-1800). In addition, two brain 133 
metastatic melanoma cell lines were used; H1 (or H1_DL2) and H2. See Supplementary Materials. 134 
We obtained written consent by the Regional Ethical Committee (#013.09) and the Norwegian 135 
Directorate of Health (#9634) before human tumor tissue was collected and stored. 136 
 137 
Animals 138 
 Female non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice were 139 
purchased from Envigo (Gannat, France). The animals were bred and maintained in our animal 140 
facility certified by the Association for Assessment and Accreditation of Laboratory Animal Care 141 
International. They were fed a standard pellet diet and provided water ad libitum. Anaesthesia was 142 
induced with 3% sevoflurane (Abbott Laboratories Ltd., Berkshire, UK) in oxygen and maintained 143 
with 1.5% sevoflurane in oxygen during all procedures unless stated otherwise. The mice were 144 
monitored daily and sacrificed when significant morbidity symptoms were observed. The National 145 
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Animal Research Authority approved all animal procedures prior to all experiments (Application 146 
#8093, approved February 13
th
, 2016).   147 
 148 
Evaluation of the in vivo toxicity of K16ApoE 149 
 The toxicity of K16ApoE was evaluated by intravenous tail vein injections of increasing 150 
concentrations of peptide into 38 NOD/SCID mice as described in Supplementary Materials and 151 
Supplementary Figure S1A.  152 
 153 
Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE-MRI) 154 
DCE-MRI was carried out using a 7 Tesla small-animal horizontal scanner (Bruker BioSpin 155 
GmbH, Ettlingen, Germany), using a 72 mm quadrature transmit coil and a 4-channel mouse brain 156 
array receive coil. The animals were placed in prone position and body temperature was maintained 157 
at 37 °C.  158 
T1 and T2 weighted spin echo scans were acquired to provide anatomical references by using 159 
fast spin echo (FSE) protocols as described in Supplementary Materials. The mice received a dose 160 
of 50 (n=5), 100 (n=11) or 200 μg (n=5) of K16ApoE dissolved in 100 μL 9 mg/mL NaCl 161 
administered through the tail vein 10, 30, 60, 120 or 240 minutes before the start of the perfusion 162 
scans. Mice in the negative control group received 100 μL 9 mg/mL NaCl. 163 
The perfusion scans were performed using dynamic contrast enhanced MRI (DCE-MRI) and 164 
analyzed using the Extended Tofts model implemented in nordicICE v2.3 (Nordic NeuroLab, 165 
Bergen, Norway) as described in Supplementary Materials.  166 
 167 
Flow cytometry  168 
RBE4 cells were pre-treated with 20 μg/mL rhodamine-conjugated K16ApoE for 45 169 
minutes and exposed to inhibitors of dynamin- and clathrin-mediated endocytosis and studied by 170 
flow cytometry. RBE4, MDCK, hCMEC/D3, H1 and H2 cells were incubated with endocytosis 171 
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inhibitors and pre-treated with 20 μg/mL K16ApoE and Alexa Fluor 647-conjugated BSA prior to 172 
flow cytometry. Both experiments are elaborated in Supplementary Materials. 173 
 174 
In vitro cell viability  175 
The viability of MDCK, MDCK II, RBE4 and hCMEC/D3 endothelial cells and H1 brain 176 
metastasis cells after treatment with K16ApoE was evaluated in vitro using a resazurin proliferation 177 
assay and for MDCK cells also a Live/Dead assay. The procedures are described in Supplementary 178 
Materials.   179 
 180 
Scanning electron microscopy 181 
  RBE4 and MDCK II cells were incubated with 0, 20, 40 or 80 μg/mL K16ApoE for 45 182 
minutes before they were fixed and prepared for scanning electron microscopy to study the 183 
morphology of the endothelial monolayers after peptide exposure. The protocol is described in 184 
Supplementary Materials.  185 
 186 
In vitro human BBB models  187 
The procedure for the cell adhesion assay carried out prior to in vitro BBB modelling 188 
experimental set-ups is described in the Supplementary Materials. 189 
Mono- and co-culture BBB models were constructed using the human astrocyte cell line SC-190 
1800 and the endothelial cell line hCMEC/D3. The resistance values, indicating increased BBB 191 
permeability, were recorded using the Electric Cell Substrate Impedance Sensing (ECIS) system 192 
and CellZScope
®
 for 2D and 3D modelling respectively, as reported previously (33). The mono- 193 
and co-cultures were treated with 0, 20, 40 or 80 µg/mL of K16ApoE and resistance was recorded 194 
until recovery of the barrier was observed. Resistance values were obtained in Ω from the ECIS 195 
system and Ω.cm
2
 from the automated sensing system, CellZScope
®
. See Supplementary Materials 196 
for a detailed description of the protocol.  197 
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In vivo biodistribution of 
125
I–K16ApoE  198 
 To study the biodistribution of the peptide, we injected 
125
I-K16ApoE intravenously into 199 
NOD/SCID mice and collected blood samples and a selection of organs and measured these for 200 
radioactivity. See Supplementary Materials for further details.   201 
 202 
In vivo treatment study 203 
 In an initial control experiment, 9 NOD/SCID mice (8 weeks old) were injected with 5×10
5
 204 
H1_DL2 cells intracardially in 0.1 mL PBS as described in Supplementary Materials and divided 205 
into two groups by simple randomization: 4 animals were injected with 200 μg K16ApoE and 5 206 
with 9 mg/mL NaCl, to exclude any treatment effects of the peptide. 207 
36 female NOD/SCID mice (8 weeks old) were then injected with 5×10
5
 H1_DL2 cells 208 
intracardially as described in Supplementary Materials. The next day, mice were by simple 209 
randomization divided into 3 treatment groups: The first group received 200 μg K16ApoE followed 210 
by 10 mg/kg dabrafenib (free base, CT-DABRF, ChemieTek, Indianapolis, IN, USA) 5 minutes 211 
later. The next group received 10 mg/kg dabrafenib and the third group received 9 mg/mL NaCl 212 
(vehicle).  213 
All solutions were administered intravenously. The mice were treated twice a week for 6 214 
weeks. See Supplementary Figure S1Β for a detailed description of the animals used.  215 
 Contrast enhanced T1 and T2 weighted MRI was conducted 4 and 6 weeks after as described 216 
in Supplementary Materials.   217 
 218 
Histology assessments  219 
 Mouse organs such as lungs, heart, liver, kidneys, colon, stomach, spleen, skin, muscle and 220 
brain were harvested after treatment with K16ApoE and fixed using 4% formaldehyde. Paraffin 221 
embedded organs were sectioned and mounted on slides. The sections were deparaffinized and 222 
stained with Hematoxylin and Eosin (H&E) for histological assessments.   223 
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Mass spectrometry  224 
 A mass spectrometry experiment was performed to confirm the presence of dabrafenib in 225 
K16ApoE combination treated NOD/SCID mice from the in vivo treatment experiment. The 226 
procedures are described in Supplementary Materials.  227 
 228 
Dynamic PET/CT   229 
 The capacity of BBB permeability from K16ApoE was further evaluated by PET/CT using 230 
18
F-albumin (∼67 kDa) and 18F-IgG (∼150 kDa) to study if also these compounds could enter the 231 
brain after administration of K16ApoE. The albumin and IgG labelling procedure prior to PET/CT 232 
as well as the dynamic scanning procedures are described in Supplementary Materials.   233 
 234 
Statistical analysis 235 
 The statistical analyses were carried out in Prism 7 for Mac, Version 7.0b (La Jolla, CA, 236 
USA). Unpaired t-tests were used to evaluate two normally distributed groups, whereas Mann-237 
Whitney tests were used to compare nonparametric data. A Mantel-Cox log-rank test was used to 238 
analyze survival data from the in vivo treatment experiment. The results are displayed as individual 239 
points with mean ± SEM or mean ± SEM. A two-tailed P-value ≤0.05 was considered significant.   240 
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Results 241 
 242 
Nontoxic doses of K16ApoE increase BBB permeability  243 
To determine the maximum tolerated dose of K16ApoE, mice were injected intravenously 244 
with increasing concentrations of peptide (50 to 1,000 μg). For peptide doses up to 400 μg, the mice 245 
showed no signs of pain or distress following systemic peptide exposure, and they all recovered 246 
from anesthesia within approximately 3 minutes (Figure 1A). Higher peptide doses led to a 247 
respiratory and/or cardiac arrest within 30 minutes (Supplementary Videos 1 and 2). Higher doses 248 
were also associated with an abnormal erythrocyte morphology (Supplementary Figure S2).  249 
 250 
K16ApoE facilitates a therapeutic window of minimum 30 minutes 251 
DCE-MRI on healthy mice demonstrated a dose-dependent effect of the peptide. K16ApoE 252 
concentrations of 50 or 100 μg was insufficient for BBB permeabilization, i.e. allowing Omniscan 253 
to enter into the extravascular, extracellular space (EES) from the blood plasma, as seen by the 254 
K
trans
 values (Figure 1B). A major leakage of Omniscan contrast agent from blood into the brain 255 
tissue was observed when administered 10 minutes after injection of 200 μg K16ApoE. This 256 
implicates that the peptide was able to successfully open the intact BBB (Figure 1C, D). 257 
Interestingly, our results also showed that the BBB was partially open for up to approximately 1 258 
hour after K16ApoE injection, reflecting a putative time frame for effective drug administration 259 
(Figure 1C, D). Other DCE-MRI parameters besides K
trans
 are listed in Supplementary Table 1. 260 
Based on the preceding, the toxicity studies above and previous literature (34), we chose to use 200 261 
μg per mouse for further in vivo experiments. 262 
 263 
Endocytic pathways are involved in cellular uptake of K16ApoE 264 
To acquire a mechanistic insight on how K16ApoE facilitates BBB permeability, we first 265 
conducted baseline studies for further in vitro experiments. We determined K16ApoE IC50 values 266 
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for 5 normal endothelial cell lines, and these were all within a relatively narrow range of 30.89–267 
86.18 μg/mL (Supplementary Figure S3A–D). For H1_DL2 cells used in the intracardiac metastasis 268 
model, the IC50 was 25.75 μg/mL (Supplementary Figure S3E).  269 
Live/Dead assays and scanning electron microscopy images of MDCK and RBE4 cells 270 
(Supplementary Figure S3F-H) showed a dose/time-dependent increase in the number of dead cells 271 
over 45 minutes (see also Supplementary Videos 3-6).  272 
We then applied flow cytometry to assess endocytic activity in RBE4 cells treated with 20 273 
μg/mL rhodamine–labelled K16ApoE. As shown in Figure 2A, high endocytic uptake of peptide 274 
was observed in the RBE4 cells (pink curve in Figure 2A). By adding chlorpromazine (dark blue 275 
curve in Figure 2A) or dynasore (brown curve in Figure 2A), which are inhibitors of clathrin and 276 
dynamin mediated endocytosis, respectively, the peptide uptake was reduced with the strongest 277 
effect seen for chlorpromazine.  278 
We then pre-treated RBE4 cells with AF647-labeled BSA and incubated with (purple curve 279 
in Figure 2B) and without K16ApoE (green curve in Figure 2B). When chlorpromazine was added 280 
as well, there was a reduction in BSA uptake (black curve in Figure 2B). The lowest BSA uptake 281 
was seen in RBE4 cells incubated with chlorpromazine and no peptide (yellow curve in Figure 2B). 282 
Corresponding experiments were carried out on MDCK, hCMEC/D3, H1 and H2 cells studying 283 
BSA uptake after pre-treatment with endocytosis inhibitors (Supplementary Figure 4). The same 284 
pattern was seen across all cell lines: The highest BSA uptake was observed for cells pretreated 285 
with K16ApoE (purple curves), whereas endocytosis inhibitors reduced this increase, 286 
chlorpromazine (yellow curves) to a larger extent than dynasore (blue curves). Dynamin-mediated 287 
endocytosis can be serum dependent. We therefore carried out the dynasore experiments with 288 
(Supplementary Figure S4) and without BSA (Figure 2).  To summarize, both clathrin- and 289 
dynamin-mediated endocytosis are likely involved in K16ApoE uptake (below IC50-doses).  290 
In order to show that also other uptake mechanisms of K16ApoE likely are involved, we 291 
investigated the uptake of AF647-conjugated BSA in RBE4 cells with (purple curves in Fig 2C and 292 
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2D) and without (green curves in Fig 2C and 2D) pre-treatment with K16ApoE. When compared to 293 
37 °C, the uptake of BSA was reduced in cells that were kept at 4° C (Figure 2D), i.e. at a 294 
temperature when endocytosis usually is abolished (Figure 2C). In conclusion, based on the above 295 
data, endocytic mechanisms are involved in peptide uptake, likely in combination with other 296 
mechanisms as described in the following.  297 
 298 
K16ApoE has lytic properties at higher concentrations (above IC50)  299 
 We then studied changes in endothelial cell monolayer surfaces in vitro following K16ApoE 300 
exposure. Scanning electron microscopy images showed that MDCK II and RBE4 cells not exposed 301 
to the peptide formed uniform monolayers (Figure 3A and Supplementary Figure S3H, 302 
respectively) with occasional protruding cells with smooth surfaces. At increasing K16ApoE 303 
concentrations, the cell surface lost the uniform morphology, and punctures in the membranes could 304 
be observed, indicating dying cells (See inserts in Figure 3A). There was an association between 305 
increasing concentrations of the peptide and the number of punctured, protruding cells. This dose-306 
dependent cell death was verified by the Live/Dead experiment (Figure 3B and Supplementary 307 
Figure S3F and G).  308 
Taken together with data presented in Supplementary Figure S2 and S3, this indicates that 309 
cell lysis is likely involved especially at higher peptide concentrations, likely due to a cationic 310 
effect leading to electrostatic interactions with negatively charged cell membranes (35), in addition 311 
to the endocytosis mechanisms indicated by flow cytometry (Figure 2). 312 
  313 
BBB integrity is restored 15 hours after treatment with the peptide 314 
Cellular adhesion was measured prior to in vitro BBB modelling using crystal violet in 96-315 
well plates after treatment with 0, 20, 40 or 80 μg/mL K16ApoE for 45 minutes. The strongest 316 
cellular adhesion was observed for untreated hCMEC/D3 cells. The adhesion potential was 317 
significantly reduced during peptide treatment in a dose-dependent manner (Supplementary Figure 318 
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S5A and B). However, although not statistically significant, there was a tendency that the adhesion 319 
potential started to recover with increasing recovery times after 45 minutes of peptide exposure. 320 
Endothelial cells exposed to 40 and 80 µg/mL showed a statistically significant increase in adhesion 321 
potential after 60 minutes (Supplementary Figure S5A).  322 
 In both human in vitro BBB models assessed, the cells were exposed to 0, 20, 40 or 80 323 
μg/mL of the peptide for 45 minutes, before they were allowed to recover for as long as deemed 324 
necessary in a mono- and co-culture model. In the mono-culture model, the endothelial cell 325 
monolayers restored their integrity within 3 hours (Figure 3C), whereas in the co-culture model 326 
with endothelial cells and astrocytes, the integrity of both cell layers was restored after 15 hours 327 
(Figure 3D).  328 
   329 
K16ApoE is eliminated from blood plasma within five minutes, through liver, kidney and 330 
spleen 331 
 The activity of 
125
I-labeled K16ApoE in blood plasma was rapidly reduced over the total 332 
measured time of 30 minutes. The most prominent decline was observed within the first minute 333 
after the peptide was injected into the tail vein, whereas subsequent values quickly reached a 334 
baseline. The curve corresponds to a half-life of K16ApoE in blood of approximately 1 minute 335 
(Supplementary Figure S6B).  336 
The biodistribution of 
125
I-K16ApoE was analysed in numerous selected organs. The highest 337 
values of 
125
I-K16ApoE accumulation were seen in the liver (164 570 cpm), kidney (160 107 cpm) 338 
and spleen (136 889 cpm), whereas the lowest counts were observed in colon (17 290 cpm), femur 339 
(14 720 cpm) and muscle tissue (13 608 cpm). Intermediate values were observed for ventricle (92 340 
533 cpm), lungs (76 554 cpm), skin (38 835 cpm) and heart (28 482 cpm). The high activity seen in 341 
the kidneys, liver and spleen suggested that elimination occurred through all of these organs 342 
(Supplementary Figure S6C).  343 
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Since 
125
I was labelled to the only histidine residue present in the peptide, the potency of the 344 
final 
125
I-K16ApoE construct only allowed us to inject a concentration of 25 μg K16ApoE without 345 
exceeding the maximum volume possible to inject intravenously in a NOD/SCID mouse. Further, 346 
since the measurements were carried out more than 30 minutes after the peptide was injected, this is 347 
a time window that does not allow major remnants of the peptide to be detected in the brain. For 348 
these reasons combined, we did not focus on the amount of peptide in the brain in this experiment, 349 
as both the concentration and time window likely is too small to see any significant uptake, as 350 
observed by DCE-MRI (Figure 1).   351 
 352 
K16ApoE does not induce acute or long-term tissue damage  353 
 Histological analysis was carried out in two separate experiments (Supplementary Figure 354 
S1). In the first experiment, healthy NOD/SCID mice were subjected to a one-time exposure of 0, 355 
200, 400, 600, 800 or 1 000 μg K16ApoE (Supplementary Figure S7A). In the second experiment, 356 
tumor-bearing animals were subjected to 200 μg K16ApoE twice a week over a period of six weeks 357 
(Supplementary Figure S7B). Representative H&E sections from brain, lungs, kidneys, liver, 358 
spleen, skin, muscle tissue, colon, stomach and heart did not reveal any pathological changes in 359 
animals from either treatment group, across both experiments (Supplementary Figures S7A and B).360 
  361 
 362 
K16ApoE improves the delivery of the BRAFi dabrafenib  363 
 We then studied whether a combined use of K16ApoE with dabrafenib (537.6 Da) could 364 
increase the therapeutic effects in a human brain metastasis animal model, compared to dabrafenib 365 
treatment alone.   366 
A small control experiment was initially carried out with injections of only K16ApoE or 367 
vehicle (saline) to evaluate whether the peptide itself had any therapeutic effects on tumor burden. 368 
No such effects were observed (Supplementary Figure S8A–C). A larger study was then done with 369 
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three treatment groups: Dabrafenib, K16ApoE and dabrafenib and vehicle. In order to minimize the 370 
number of animals used, the K16ApoE alone group was not repeated. 371 
The mean number of tumors as well as the mean total tumor volume in animals treated with 372 
a combination of K16ApoE and dabrafenib decreased at weeks 4 and 6, compared to control 373 
animals (vehicle) or animals treated with dabrafenib only (Figure 4A–C). No statistically significant 374 
differences could be found in tumor numbers or tumor volumes between the dabrafenib group and 375 
the control group at week 4 and 6, indicating that dabrafenib treatment alone was not effective. 376 
 Kaplan-Meier curves revealed no difference in survival between vehicle and dabrafenib 377 
treated animals whereas the combinatorial treatment group had a significant survival benefit (Figure 378 
4D).  379 
 380 
K16ApoE treatment causes an uptake of dabrafenib in the brain parenchyma 381 
A pilot mass spectrometry imaging experiment revealed that dabrafenib was taken up in the 382 
brain in mice treated with a co-injection of peptide and dabrafenib, as shown in Supplementary 383 
Figure S9A. A negative control animal treated with vehicle is presented in Supplementary Figure 384 
S9B, where no uptake is detected. Dabrafenib was fragmented in two segments, namely at m/z 385 
480.1 and 344.1 as seen in Supplementary Figure S9C.  386 
 387 
K16ApoE facilitates blood-brain barrier penetration of large molecules  388 
 To test the potential of K16ApoE to carry even larger molecules than dabrafenib across the 389 
BBB, we injected 200 μg K16ApoE followed by 
18
F-albumin (∼67 kDa) or 18F-IgG (∼150 kDa) 390 
and performed subsequent dynamic PET/CT brain imaging. Over 30–60 minutes, we observed a 391 
significant increase in average standardized uptake values (SUVmean) in peptide–injected mice as 392 
compared to vehicle–treated mice for both 
18
F-albumin (Figure 5A) and 
18
F-IgG (Figure 5B). This 393 
implies leakage of the radiolabeled molecules from the blood plasma and into the EEC. Thus, 394 
K16ApoE facilitates the delivery of compounds with a molecular weight of up to at least 150 kDa. 395 
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Discussion  396 
The delivery of therapeutic drug concentrations across the BBB and into metastatic lesions 397 
remains a critical issue in the treatment of brain metastases. In the smallest lesions not detected by 398 
clinical MRI, the BBB is presumably intact. As the brain metastases progress, the barriers develop a 399 
heterogeneous permeability to different-sized molecules, still with many metastases showing minor 400 
or no permeability at all (15). Thus, efficient drug delivery to the brain lesions is often 401 
compromised, necessitating the need for strategies to increase the leakiness of the BBB (30). Here, 402 
we describe a treatment strategy using a BBB permeabilizing peptide and thereby improving the 403 
delivery of dabrafenib (537.6 Da), which previously has demonstrated profound effects towards 404 
extracranial melanomas with BRAF mutations. Although the anatomical distribution of dabrafenib 405 
is superior to several other BRAFis (9), the drug does not readily penetrate into the brain 406 
parenchyma if the BBB is intact. Here we show that our treatment strategy inhibits the progression 407 
of BRAF
V600E
 mutated melanoma brain metastases, ascribed to an improved drug delivery across 408 
the BBB.  409 
In a previous study with K16ApoE, Evans blue (MW ∼0.96 kDa) was injected 10 minutes 410 
after administering the peptide, and the results indicated that a therapeutic window of 411 
approximately 60 minutes was facilitated (34). We used DCE-MRI which is a quantitative and 412 
highly sensitive MRI technique to validate these results. The observed increase in K
trans
 values 413 
demonstrates a genuine pharmacodynamic increase in BBB permeability and thus perfusion (36), 414 
and this was directly attributable to peptide action.  415 
However, although it has been shown by us and others that K16ApoE is able to 416 
permeabilize the BBB, the specific mechanisms responsible for this effect have not been firmly 417 
established (32,34,37). Meng and colleagues have previously seen that K16ApoE likely promotes 418 
endocytosis into endothelial cells (37). Our findings indicate that there are likely several 419 
mechanisms involved, including loss in cell membrane integrity and lytic properties in addition to 420 
endocytosis, especially at higher peptide concentrations. We show that the cellular uptake of 421 
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K16ApoE at lower doses (i.e. 20 g/mL) was reduced by dynasore and chlorpromazine, inhibitors 422 
of dynamin-dependent and clathrin-mediated endocytosis, respectively. Our data may suggest that 423 
clathrin-mediated endocytosis is the most active one of these two mechanisms, which is also in line 424 
with the literature (38). We found that peptide-mediated uptake of BSA was still present at low 425 
temperatures (4 °C) when endocytosis is significantly reduced, although at reduced levels. This 426 
adds to the hypothesis that also other cellular uptake-mechanisms may be involved. For instance, 427 
our scanning electron microscopy data indicated that the peptide exerted a dose-dependent, toxic 428 
effect on the cells, which has also been reported previously (37). At increasing concentrations, more 429 
cells with punctured cell membranes were observed (Figure 3A), suggesting also a lytic effect at 430 
higher concentrations. These findings were supported by our fluorescence time lapse study, which 431 
also indicated that the cells were relatively unaffected by the peptide during the first minute of 432 
exposure. In addition, the half-life of K16ApoE in the blood was approximately one minute, which 433 
taken together implies that relatively large doses of peptide (above the IC50 doses) may be injected 434 
safely into the bloodstream. This is also supported by the in vivo toxicity study summarized in 435 
Figure 1A.  436 
The endothelial cell integrity after exposure to the peptide was studied using in vitro BBB 437 
models and by investigating peptide action on proteins important in the assembly and maintenance 438 
of tight junctions. The peptide reduced the endothelial barrier integrity as measured using both 439 
ECIS (Figure 3C) and cellZScope (Figure 3D). Within 3 hours, the endothelial monolayer was 440 
restored, whereas the co-culture system remodelled the barrier integrity after 15 hours. This time 441 
discrepancy may be explained based on the fact that the methods are not directly comparable to 442 
each other. In the ECIS system, the output values are normalized before the resistance values can be 443 
regarded as absolute, while the measured resistance in cellZscope is directly attributable to the cell 444 
layers. Also, in the ECIS measurements there was only one layer of cells while a co-culture was 445 
constructed for the cellZScope. Thus, both cell lines had to recover for the barrier to be intact. 446 
Nevertheless, the results from both systems indicate that the BBB is restored after being transiently 447 
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exposed to K16ApoE. In addition to its added mechanistic information, these experiments also 448 
validate the peptide action in a 3D human system.  449 
In the in vivo treatment study summarized in Figure 4, 200 g K16ApoE was administered 450 
intravenously into each mouse, and with a blood volume of approximately 1.5 mL, this corresponds 451 
to a peptide concentration of around 133 g/mL blood. No side effects were observed after these 452 
injections, presumably due to the quick clearance from the blood, which occurred mainly through 453 
the liver, spleen and kidneys. Meng and colleagues argued that there was a positive correlation 454 
between toxic effects of the peptide at higher concentrations and BBB permeabilization. They also 455 
indicated that interactions of the peptide with adjacent erythrocytes resulted in the formation of 456 
microthrombi, which could be the underlying mechanism of toxicity (37). Taken together with our 457 
findings of hemolysis after treatment with K16ApoE, the injection of 200 μg K16ApoE per mouse 458 
thus represents a compromise between a favorable BBB permeable effect of the peptide and 459 
potential unwanted toxic side effects. 460 
Our drug delivery strategy involved intravenous administration of a drug that normally is 461 
given orally to patients, thus several potential effects on the drug from the gastrointestinal tract such 462 
as degrading enzymes, low pH or heterogenous blood perfusion were not taken into consideration. 463 
We also administered 10 mg/kg to the mice twice a week, while in the clinic, patients are 464 
commonly given 2 × 150 mg dabrafenib daily, which corresponds to 4 mg/kg for a 75 kg patient. 465 
Although the concentrations are not directly comparable, our findings clearly suggest that 466 
dabrafenib represents an effective treatment for melanoma brain metastases, provided successful 467 
entry through the BBB. The amount of injected drug that penetrated the BBB and accumulated 468 
within the mouse brains was not quantified. However, a pilot mass spectrometry experiment of 469 
brain tissue harvested from control mice and K16ApoE + dabrafenib treated mice was performed, 470 
showing the presence of dabrafenib within the brains after peptide administration. Dabrafenib was 471 
not found in brains from control mice. Further experiments should be carried out aiming to quantify 472 
the detected amount of drug when co-injected with K16ApoE.  473 
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The histopathological examination performed by an experienced neuropathologist showed 474 
that no changes in organ histology could be found after administering a single high-dose (1,000 g) 475 
of peptide to the mice, or at the end of the dabrafenib study, when the mice had been given 12 476 
injections of 200 g K16ApoE over six weeks.  477 
As a final experiment, we used dynamic PET/CT to study whether the BBB was permeable, 478 
following K16ApoE exposure, to even larger molecules. We detected 
18
F-labelled albumin (MW 479 
∼67 kDa) and IgG (MW ∼150 kDa) in brain tissue. Although drug uptake across the BBB or BTB is 480 
not only limited to size, our results indicate that K16ApoE can facilitate the delivery of substances 481 
in the size range of immune checkpoint inhibitors to patients with brain metastases. Examples 482 
include ipilimumab (MW ∼148 kDa), which targets cytotoxic T-lymphocyte antigen 4 (CTLA4) or 483 
inhibitors of PD-1/PD-L1 such as for instance nivolumab (MW ∼143 kDa) and atezolizumab (MW 484 
∼145 kDa), respectively. Thus, for future investigations, we aspire to carry out in vivo treatment 485 
experiments with immune checkpoint inhibitors on melanoma brain metastases.  486 
In conclusion, the use of K16ApoE seems to be a promising strategy to improve drug 487 
delivery across the BBB. Potential toxicity issues preclude direct translation into the clinic as of 488 
today, warranting further studies with the peptide, which is also the case with several other methods 489 
of permeabilizing the BBB. Our strategy using K16ApoE serves as an easy, non-invasive and 490 
reliable tool to establish treatment effects in vivo with agents that otherwise do not penetrate the 491 
BBB. 492 
  493 
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Figure legends 641 
 642 
Figure 1 643 
K16ApoE creates a time window for therapy for at least 30 minutes. A, Survival curves after 644 
K16ApoE dose escalation experiments. B, Scatter plots of the blood-to-tissue transfer constant 645 
(K
trans
) demonstrate a dose-dependent reduction of contrast agent transfer from blood to tissue with 646 
decreasing peptide concentrations (n=5-10 mice). Mean ± SEM. C, Representative anatomical 647 
contrast enhanced T1 weighted MR images (top row) and parametric MR images (K
trans
 and AUC 648 
maps; two bottom rows) of coronal brain sections of a control mouse are seen to the left. Scalebar = 649 
2.5 mm. D, the quantified K
trans
 analysis demonstrates leakage of contrast agent from blood to tissue 650 
10 and 30 minutes after injection of 200 µg of K16ApoE, compared to control animals (n=5-10 651 
mice). Mean ± SEM. Abbreviations: K
trans
: transfer constant, T1CE: contrast enhanced T1 weighted 652 
scan, AUC: area under curve, **: p < 0.01.  653 
 654 
Figure 2  655 
Mechanistic studies of the in vitro effects of K16ApoE. A, Flow cytometry data showing the effects 656 
of two endocytosis inhibitors, chlorpromazine and dynasore after 30 minutes of incubation, on 657 
K16ApoE uptake in RBE4 cells after 45 minutes of continued incubation. B, Flow cytometry data 658 
on uptake of BSA into cells while pre-treating RBE4 cells with chlorpromazine for 30 minutes, 659 
with and without using the peptide for 45 minutes. C, Flow cytometry data showing uptake of BSA 660 
at 37 °C and at D, 4 °C after incubating the cells for one hour. Abbreviations: RBE4: rat brain 661 
endothelial cells 4, BSA: bovine serum albumin, cp: chlorpromazine. 662 
 663 
Figure 3  664 
Integrity of an in vitro model of the blood-brain barrier after exposure to the peptide. A, Scanning 665 
electron microscopy images demonstrating nonspecific cell monolayer disruptions in preparations 666 
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of MDCK II cells. Inserts in micrographs with cells exposed to 0 µg/mL K16ApoE demonstrate 667 
smooth cell membranes, whereas cells exposed to 80 µg/mL of the peptide have punctured cell 668 
membranes. All scalebars 20 µm. B, Cell death as a result of corresponding peptide concentrations 669 
as seen by Live/Dead staining of MDCK cells. Scalebar 50 μm. C, Recorded resistance values 670 
using the ECIS system in a monolayer of hCMEC/D3 endothelial cells. The resistance was restored 671 
3 h after peptide exposure. D, Measured resistance (TEER) values using the CellZScope system in a 672 
co-culture consisting of astrocytes and hCMEC/D3 endothelial cells. Barrier integrity was restored 673 
15 h after peptide exposure. Cell illustration from Somersault1824 (www.somersault1824.com). 674 
Abbreviations: ECIS: Electric cell substrate impedance sensing, TEER: transendothelial/epithelial 675 
electrical resistance. 676 
 677 
Figure 4  678 
Combined treatment with K16ApoE and dabrafenib inhibits tumor development and increases 679 
animal survival in an animal model of melanoma brain metastasis. A, The mean, total number of 680 
tumors in the mouse brains four (left) and six (right) weeks after start of treatment. Mann-Whitney 681 
statistical test. Mean ± SEM. B, The mean, total tumor volumes in the mouse brains four (left) and 682 
six (right) weeks after start of treatment. Mean ± SEM. C, Representative CE T1 weighted and T2 683 
weighted MR images from each treatment group at week four and six. Scalebar 2 mm. D, Survival 684 
curves for all animals in the treatment study. Abbreviations: *: p<0.05, **: p<0.01, ****: 0.0001, 685 
CE T1: contrast enhanced T1 weighted MR images obtained 5 minutes after injection of Omniscan, 686 
T2: T2 weighted MR images.   687 
 688 
Figure 5 689 
K16ApoE facilitates the delivery of large compounds across the BBB. A, Standardized uptake of 690 
18
F-albumin into brain tissue, monitored by a 30 minutes dynamic PET/CT scan. Each mouse was 691 
scanned twice, with and without a prior injection of 200 µg K16ApoE, on separate days (n=3 mice). 692 
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The mean standard uptake value (SUVmean) was calculated within an ellipsoidal volume of interest, 693 
delineating the skull. Mean ± SEM. B, Standardized uptake of 
18
F-IgG into brain tissue, monitored 694 
by a 60 minutes dynamic PET/CT scan. Each mouse was scanned twice, with and without a prior 695 
injection of 200 µg K16ApoE, on separate days (n=7 mice). The mean standard uptake value 696 
(SUVmean) was calculated. Mean ± SEM. Abbreviations: SUV: standardized uptake values,
 18
F: 697 
Fluorine-18, PET: positron emission tomography, IgG: immunoglobulin G, *: p<0.05. 698 
 699 





